NEW YORK, NY, June 3, 2015 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc. today announced that they published an Abstract, in conjunction with the 2015 ASCO Annual Meeting held May 29 - June 2th, 2015 in Chicago, Illinois.
The publication only abstract titled: Prospective-retrospective analysis of a novel blood-based combinatorial biomarker assay (liquid biopsy) in 859 patients to demonstrate the benefit of combining biomarker data with imaging to differentiate benign breast lesions from invasive breast cancer in women, can be found in its entirety at e22260.
About Provista Diagnostics, Inc.
Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women's cancer, such as breast and gynecologic cancers. Provista Diagnostics' state-of-the-art, high complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and certified by the Centers for Medicare and Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA).
Additional information about Provista Diagnostics is available at ProvistaDx.com
Information about Provista Diagnostics' clinical trials is available at ClinicalTrials.gov
About The ASCO Annual Meeting
The American Society of Clinical Oncology (ASCO) Annual Meeting brings together 30,000 oncology professionals from around the world. Education sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Science sessions present the latest ground-breaking research in oral and poster format.
Additional information about ASCO Annual Meeting can be found at asco.org.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
David R. Holmes
Provista Diagnostics, Inc.
Source:Provista Diagnostics, Inc.